Key Takeaways
- Robert F. Kennedy Jr. plans to divest from several companies, including CRISPR Therapeutics and Dragonfly Therapeutics, if confirmed as HHS secretary.
- He holds investments in both biotech firms and other companies like Amazon and Apple, with annual earnings from Dragonfly.
- Currently, Dorothy Fink, M.D., serves as the acting secretary of the Department of Health and Human Services.
Divestment Plans if Confirmed as HHS Secretary
Robert F. Kennedy Jr., the nominee for U.S. Secretary of Health and Human Services (HHS), has publicly stated his intention to divest from several biotechnology companies if he is confirmed. This includes CRISPR Therapeutics and Dragonfly Therapeutics, as disclosed in a letter to the U.S. Office of Government Ethics dated January 21. Under the plan, RFK Jr. aims to divest from these investments within 90 days of his confirmation.
Kennedy’s investment in CRISPR Therapeutics is valued between $1,001 and $15,000. He has clarified that he does not generate any income from this investment. In contrast, his stake in Dragonfly Therapeutics is between $15,001 and $50,000, yielding annual dividends of between $1,001 and $2,500. Additionally, his letter included a commitment to refrain from any personal or significant participation in entities that could financially impact him until these investments are fully divested.
Aside from his investments, RFK Jr. has substantial income from his role as a partner at his law firm, which recently rebranded from Kennedy & Madonna to Madonna & Madonna. His annual earnings from the law firm are approximately $8.8 million, marking a significant financial base separate from his biotech investments.
As of now, Kennedy’s Senate confirmation hearing has yet to be scheduled. The Washington Post reports that delays are occurring as the Senate continues to review his financial disclosures. In the interim period, Dorothy Fink, M.D., has taken over as acting HHS secretary, ensuring ongoing leadership in the department while Kennedy awaits confirmation.
These developments highlight the cautious approach Kennedy is taking toward potential conflicts of interest related to his investments, as well as the procedural dynamics involved in his ascent to a pivotal cabinet position.
The content above is a summary. For more details, see the source article.